676 Pepinemab, a semaphorin 4D inhibitor, in combination with pembrolizumab induced formation of organized lymphoid aggregates in phase 1b/2 study for first-line treatment of R/M HNSCC (KEYNOTE-B84)
Main Authors: | Elizabeth Evans, Nagashree Seetharamu, Crystal Mallow, Maurice Zauderer, Barbara Burtness, Marya Chaney, Alexander Spira, Conor Steuer, Tarek Mekhail, J Thaddeus Beck, Douglas Adkins, Terrence Fisher, Amber Foster, John Leonard, Nabil F Saba, Megan Baumgart, Steven Hager, Christopher Chay |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26hi T cell in patients with resectable stage III melanoma
by: Brian Burns, et al.
Published: (2023-11-01) -
<br><b>Keynotes</b>
by: Jan Erik Frantsvåg
Published: (2015-03-01) -
<br><b>Keynotes</b>
by: Jan Erik Frantsvåg
Published: (2015-03-01) -
Semaphorin-3F/Neuropilin-2 Transcriptional Expression as a Predictive Biomarker of Occult Lymph Node Metastases in HNSCC
by: Carla Meler-Claramonte, et al.
Published: (2022-04-01) -
Keynotes
Published: (2023-05-01)